Literature DB >> 7678428

Antibody responses of visceral leishmaniasis patients to gp63, a major surface glycoprotein of Leishmania species.

W G Shreffler1, J M Burns, R Badaró, H W Ghalib, L L Button, W R McMaster, S G Reed.   

Abstract

A major surface glycoprotein of Leishmania parasites, gp63, is highly conserved among species and is expressed in both infective and intracellular stages. Although much is known about its role in entry and survival in host macrophages, patient antibody responses to this glycoprotein have not been well characterized. The prevalence of anti-gp63 antibody in sera of leishmaniasis patients was evaluated by ELISA. Sera from most acute visceral leishmaniasis patients (84%) from Brazil and Sudan had notably high levels of antibody to recombinant (r) gp63. Sera from other forms of leishmaniasis and from other diseases did not contain significantly elevated levels of anti-gp63 antibody. These results indicate that rgp63 might be a useful constituent of a defined serologic test for visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7678428     DOI: 10.1093/infdis/167.2.426

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  23 in total

1.  Immunoenzymatic assay for the diagnosis of American tegumentary leishmaniasis using soluble and membrane-enriched fractions from infectious Leishmania (Viannia) braziliensis.

Authors:  Jamyra Iglesias Cataldo; Fernanda Carvalho de Queiroz Mello; Eliame Mouta-Confort; Maria de Fátima Madeira; Armando de Oliveira Schubach; Marcelo da Silva Genestra; Flávia Coelho Ribeiro; Célia de Fátima Moreira-Venâncio; Sônia Regina Lambert Passos
Journal:  J Clin Lab Anal       Date:  2010       Impact factor: 2.352

2.  Multicomponent chimeric antigen for serodiagnosis of canine visceral leishmaniasis.

Authors:  M Soto; J M Requena; L Quijada; C Alonso
Journal:  J Clin Microbiol       Date:  1998-01       Impact factor: 5.948

3.  Detection of specific antibody isotypes and subtypes before and after treatment of American visceral leishmaniasis.

Authors:  V L da Matta; S Hoshino-Shimizu; R Dietze; C E Corbett
Journal:  J Clin Lab Anal       Date:  2000       Impact factor: 2.352

4.  Antibody response against a Leishmania donovani amastigote-stage-specific protein in patients with visceral leishmaniasis.

Authors:  E Ghedin; W W Zhang; H Charest; S Sundar; R T Kenney; G Matlashewski
Journal:  Clin Diagn Lab Immunol       Date:  1997-09

5.  Performance of immunoblotting in diagnosis of visceral Leishmaniasis in human immunodeficiency virus-Leishmania sp.-coinfected patients.

Authors:  G Santos-Gomes; S Gomes-Pereira; L Campino; M D Araújo; P Abranches
Journal:  J Clin Microbiol       Date:  2000-01       Impact factor: 5.948

6.  Dual role of the Leishmania major ribosomal protein S3a homologue in regulation of T- and B-cell activation.

Authors:  A Cordeiro-Da-Silva; M C Borges; E Guilvard; A Ouaissi
Journal:  Infect Immun       Date:  2001-11       Impact factor: 3.441

7.  Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.

Authors:  Farhat Afrin; Ravindran Rajesh; Khairul Anam; Meenakshisundram Gopinath; Swati Pal; Nahid Ali
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

8.  Evaluation of cleaving agents other than trypsin in direct agglutination test for further improving diagnosis of visceral leishmaniasis.

Authors:  A el Harith; S Chowdhury; A al-Masum; S Semião-Santos; E Karim; S el-Safi; I Haque
Journal:  J Clin Microbiol       Date:  1995-08       Impact factor: 5.948

9.  Characterization of an I-E-restricted, gp63-specific, CD4-T-cell clone from Leishmania major-resistant C3H mice that secretes type 2 cytokines and exacerbates infection with L. major.

Authors:  Cynthia M Theodos; Robin V Morris; Jeanette V Bishop; Jeremy D Jones; W Robert McMaster; Richard G Titus
Journal:  Infect Immun       Date:  2004-08       Impact factor: 3.441

10.  Synthetic peptide-based enzyme-linked immunosorbent assay for serodiagnosis of visceral leishmaniasis.

Authors:  C Fargeas; M Hommel; R Maingon; C Dourado; M Monsigny; R Mayer
Journal:  J Clin Microbiol       Date:  1996-02       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.